Astrana Health initiated as buy at Needham on valuation
I'm PortAI, I can summarize articles.
Needham initiated coverage of Astrana Health (ASTH) with a Buy rating and a $28 price target, citing a valuation disconnect between hospitals and the health tech firm. Analyst Matthew Shea noted Astrana's current trading level is below that of hospital operators and sees shares as undervalued. He highlighted the company's integration of hospital operations into its value-based care network and its superior growth profile and margin potential.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments